Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022

In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% con...

Descripción completa

Detalles Bibliográficos
Autores principales: Castilla, Jesús, Lecea, Óscar, Martín Salas, Carmen, Quílez, Delia, Miqueleiz, Ana, Trobajo-Sanmartín, Camino, Navascués, Ana, Martínez-Baz, Iván, Casado, Itziar, Burgui, Cristina, Egüés, Nerea, Ezpeleta, Guillermo, Ezpeleta, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389855/
https://www.ncbi.nlm.nih.gov/pubmed/35983774
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.33.2200619
Descripción
Sumario:In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05–0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47–2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.

Ejemplares similares